Brief: HKEX Announces Disciplinary Action Against Shanghai Henlius Biotech
02/09/2025 11:33
Sept 2 (Reuters) - HKEX: DISCIPLINARY ACTION AGAINST SHANGHAI HENLIUS BIOTECH CRITICISES FORMER EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER SHANGHAI HENLIUS BIOTECH AND FORMER CEO DID NOT CONTEST RESPECTIVE BREACHES, AGREED TO ACCEPT SANCTIONS Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln